Leachim (Travoprost)

Travoprost activates prostaglandin F (FP) receptors in the eye, stimulating the uveoscleral pathway to increase outflow of aqueous humor. This enhanced drainage reduces intraocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension.

The prescribed dose is determined by the treating ophthalmologist. Typically, one drop of Leachim is instilled into the affected eye(s) once daily in the evening, but the exact regimen should follow the clinician’s instructions.

Safety data for travoprost in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any possible risk to the fetus or infant.

To order Leachim, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Leachim (travoprost) belongs to the prostaglandin analog class, similar to latanoprost and bimatoprost. All three lower intraocular pressure by increasing uveoscleral outflow, but individual response, side‑effect profiles, and tolerability may differ, making clinician selection based on patient-specific factors.

Leachim eye drops should be stored at room temperature, below 25 °C, in the original container. Protect the bottle from direct sunlight and moisture, and keep the cap tightly closed when not in use to maintain sterility.

Instill one drop of Leachim into the conjunctival sac of the prescribed eye(s) once daily, preferably in the evening. Tilt the head back, pull down the lower eyelid to create a small pocket, and avoid touching the tip of the bottle to the eye or any surface.

Serious adverse events, though rare, include uveitis, macular edema, severe allergic reactions, and sudden vision loss. Patients should seek immediate medical attention if they experience persistent eye pain, significant visual changes, or signs of intraocular inflammation.

Leachim is contraindicated in patients with known hypersensitivity to travoprost or any component of the formulation, and in those with active ocular inflammation such as uveitis or severe conjunctivitis. Caution is also advised for individuals with a history of ocular infections.